Novo Nordisk
NVO
#107
Rank
โ‚น15.550 T
Marketcap
โ‚น3,528
Share price
-2.70%
Change (1 day)
-16.42%
Change (1 year)

Novo Nordisk A / S produces and markets pharmaceutical products and services. Since its founding in Denmark in 1923, the company has developed into a leading company in the diabetes sector worldwide.

EPS for Novo Nordisk (NVO)

EPS in 2026 (TTM): โ‚น367.78

According to Novo Nordisk's latest financial reports the company's current EPS (TTM) is โ‚น368.13. In 2025 the company made an earnings per share (EPS) of โ‚น331.27 an increase over its 2024 EPS that were of โ‚น305.36.

EPS history for Novo Nordisk from 2016 to 2026

Annual EPS

Year EPS Change
2026 (TTM)โ‚น367.7811.02%
2025โ‚น331.278.48%
2024โ‚น305.36
2016โ‚น104.04

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Pfizer
PFE
โ‚น66.24-82.01%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
โ‚น2,882 682.87%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
โ‚น184.77-49.81%๐Ÿ‡ซ๐Ÿ‡ท France
Bristol-Myers Squibb
BMY
โ‚น421.69 14.55%๐Ÿ‡บ๐Ÿ‡ธ USA